Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:OCRX
- CUSIP: N/A
- Web: www.ocerainc.com
Capitalization:- Market Cap: $27.33 million
- Outstanding Shares: 26,510,000
Average Prices:- 50 Day Moving Avg: $1.13
- 200 Day Moving Avg: $1.08
- 52 Week Range: $0.52 - $3.15
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.07
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $550,000.00
- Price / Sales: 49.65
- Book Value: $0.35 per share
- Price / Book: 2.94
Profitability:- EBIDTA: ($24,060,000.00)
- Net Margins: -4,416.26%
- Return on Equity: -175.02%
- Return on Assets: -89.76%
Debt:- Current Ratio: 1.70%
- Quick Ratio: 1.70%
Misc:- Average Volume: 181,047 shs.
- Beta: 2.28
- Short Ratio: 5.3
Frequently Asked Questions for Ocera Therapeutics (NASDAQ:OCRX)
What is Ocera Therapeutics' stock symbol?
Ocera Therapeutics trades on the NASDAQ under the ticker symbol "OCRX."
How were Ocera Therapeutics' earnings last quarter?
Ocera Therapeutics, Inc. (NASDAQ:OCRX) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. Ocera Therapeutics had a negative return on equity of 175.02% and a negative net margin of 4,416.26%. View Ocera Therapeutics' Earnings History.
Where is Ocera Therapeutics' stock going? Where will Ocera Therapeutics' stock price be in 2017?
5 equities research analysts have issued 1 year price targets for Ocera Therapeutics' shares. Their forecasts range from $1.00 to $10.00. On average, they expect Ocera Therapeutics' stock price to reach $4.50 in the next year. View Analyst Ratings for Ocera Therapeutics.
Who are some of Ocera Therapeutics' key competitors?
Some companies that are related to Ocera Therapeutics include Chiasma (CHMA), Mirna Therapeutics (MIRN), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS), Sonoma Pharmaceuticals (SNOA), Onconova Therapeutics (ONTX), Catalyst Biosciences (CBIO), Argos Therapeutics (ARGS), Auxilium Pharmaceuticals (AUXL), Baxalta (BXLT), Horizon Therapeutics (HPTX), Ocera Therapeutics (TZYM), Transition Therapeutics (TTHI) and Vitae Pharmaceuticals (VTAE).
Who are Ocera Therapeutics' key executives?
Ocera Therapeutics' management team includes the folowing people:
- Linda S. Grais M.D., President, Chief Executive Officer, Director
- Michael Byrnes, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
- Stan Bukofzer M.D., Chief Medical Officer
- Steven P. James, Lead Independent Director
- Willard H. Dere M.D., Director
- Nina S. Kjellson, Independent Director
- Anne M. VanLent, Independent Director
- Eckard Weber M.D., Independent Director
Who owns Ocera Therapeutics stock?
Ocera Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include VHCP Management II LLC (4.59%), Vanguard Group Inc. (2.83%), Hikari Power Ltd (1.42%) and Virtu KCG Holdings LLC (0.81%). Company insiders that own Ocera Therapeutics stock include Gaurav Aggarwal, Linda S Grais, Michael Byrnes and Stan Bukofzer. View Institutional Ownership Trends for Ocera Therapeutics.
Who sold Ocera Therapeutics stock? Who is selling Ocera Therapeutics stock?
Who bought Ocera Therapeutics stock? Who is buying Ocera Therapeutics stock?
Ocera Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC and Hikari Power Ltd. Company insiders that have bought Ocera Therapeutics stock in the last two years include Gaurav Aggarwal, Linda S Grais, Michael Byrnes and Stan Bukofzer. View Insider Buying and Selling for Ocera Therapeutics.
How do I buy Ocera Therapeutics stock?
Shares of Ocera Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocera Therapeutics' stock price today?
One share of Ocera Therapeutics stock can currently be purchased for approximately $1.03.
MarketBeat Community Rating for Ocera Therapeutics (NASDAQ OCRX)MarketBeat's community ratings are surveys of what our community members think about Ocera Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ocera Therapeutics (NASDAQ:OCRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $4.50 (336.89% upside) |
Analysts' Ratings History for Ocera Therapeutics (NASDAQ:OCRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/24/2017 | Aegis | Reiterated Rating | Buy | $3.00 | Low |  |
| 5/10/2017 | HC Wainwright | Reiterated Rating | Buy | $4.00 | High | |
| 1/31/2017 | JMP Securities | Downgrade | Outperform -> Market Perform | | N/A | |
| 1/30/2017 | Stifel Nicolaus | Downgrade | Buy -> Hold | $1.00 | N/A | |
| 10/24/2016 | Brean Capital | Set Price Target | Buy | $10.00 | N/A | |
| 3/6/2016 | Cowen and Company | Reiterated Rating | Buy | $11.00 | N/A | |
(Data available from 8/19/2015 forward)
Earnings History for Ocera Therapeutics (NASDAQ:OCRX)Earnings History by Quarter for Ocera Therapeutics (NASDAQ OCRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | Q2 2017 | ($0.24) | ($0.23) | | | View | N/A | |
| 5/9/2017 | Q1 2017 | ($0.24) | ($0.28) | | | View | Listen | |
| 4/29/2016 | Q1 | ($0.33) | ($0.36) | | $0.03 million | View | N/A | |
| 3/3/2016 | Q415 | ($0.33) | ($0.34) | | $0.02 million | View | N/A | |
| 8/3/2015 | Q215 | ($0.40) | ($0.46) | | $0.04 million | View | N/A | |
| 4/30/2015 | Q115 | ($0.29) | ($0.34) | | $0.03 million | View | N/A | |
| 3/11/2015 | Q414 | ($0.46) | ($0.28) | | $0.03 million | View | N/A | |
| 11/13/2014 | Q314 | ($0.50) | ($0.34) | | $0.23 million | View | N/A | |
| 8/11/2014 | Q114 | ($0.45) | ($0.46) | | $0.03 million | View | N/A | |
| 5/8/2014 | | ($0.43) | ($0.27) | | $0.05 million | View | N/A | |
| 3/13/2014 | Q413 | ($0.21) | ($0.48) | $2.93 million | $52.00 million | View | N/A | |
| 11/13/2013 | Q3 13 | | ($0.77) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ocera Therapeutics (NASDAQ:OCRX)Current Year EPS Consensus Estimate: $-0.98 EPS
Next Year EPS Consensus Estimate: $-0.96 EPS
Dividend History for Ocera Therapeutics (NASDAQ:OCRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ocera Therapeutics (NASDAQ:OCRX)Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 20.86%
Insider Trades by Quarter for Ocera Therapeutics (NASDAQ:OCRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/28/2017 | Michael Byrnes | CFO | Buy | 3,000 | $1.28 | $3,840.00 | |
| 12/7/2016 | Linda S Grais | Insider | Buy | 7,000 | $2.14 | $14,980.00 | |
| 10/13/2016 | Stan Bukofzer | Insider | Buy | 2,500 | $2.64 | $6,600.00 | |
| 3/4/2016 | Linda S Grais | CEO | Buy | 3,000 | $3.19 | $9,570.00 | |
| 1/22/2016 | Linda S Grais | CEO | Buy | 10,000 | $2.38 | $23,800.00 | |
| 1/15/2016 | Gaurav Aggarwal | Insider | Buy | 10,000 | $2.15 | $21,500.00 | |
| 1/15/2016 | Michael Byrnes | CFO | Buy | 3,500 | $2.07 | $7,245.00 | |
| 6/23/2015 | Wendall Wierenga | Director | Buy | 5,000 | $3.71 | $18,550.00 | |
| 5/7/2015 | Rajiv Patni | Insider | Buy | 5,050 | $3.97 | $20,048.50 | |
| 5/6/2015 | Gaurav Aggarwal | Insider | Buy | 7,500 | $3.62 | $27,150.00 | |
| 5/6/2015 | Linda S Grais | CEO | Buy | 30,000 | $3.73 | $111,900.00 | |
| 5/6/2015 | Michael Byrnes | CFO | Buy | 2,500 | $3.61 | $9,025.00 | |
| 10/1/2014 | Michael Byrnes | VP | Buy | 2,000 | $4.81 | $9,620.00 | |
| 7/11/2014 | Linda S Grais | CEO | Buy | 10,000 | $5.93 | $59,300.00 | |
| 7/11/2014 | Sharon Tetlow | CFO | Buy | 3,000 | $5.83 | $17,490.00 | |
| 7/15/2013 | Brian K Halak | Major Shareholder | Buy | 995,618 | $6.03 | $6,003,576.54 | |
| 7/15/2013 | Michael Powell | Director | Buy | 391,166 | $6.03 | $2,358,730.98 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ocera Therapeutics (NASDAQ:OCRX)
Latest Headlines for Ocera Therapeutics (NASDAQ:OCRX)
| Source: |
|
| Date | Headline |
|---|
 | Transition Therapeutics (TTHI) versus Ocera Therapeutics (OCRX) Financial Contrast
www.americanbankingnews.com - August 19 at 2:26 AM |
 | Ocera Therapeutics: When A Drug Fails, But Actually Works - Seeking Alpha
seekingalpha.com - August 10 at 6:26 AM |
| Ocera Therapeutics Inc (NASDAQ:OCRX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 10:24 AM |
| Ocera Therapeutics, Inc. (NASDAQ:OCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 2 at 6:00 PM |
 | Ocera Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 6:32 AM |
| Financial Survey: Ocera Therapeutics (NASDAQ:OCRX) versus Strongbridge Biopharma PLC (SBBP)
www.americanbankingnews.com - July 27 at 8:11 PM |
| Ocera Therapeutics, Inc. (OCRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 11 at 10:32 AM |
| Zacks: Brokerages Expect Ocera Therapeutics, Inc. (NASDAQ:OCRX) to Post -$0.22 EPS
www.americanbankingnews.com - July 3 at 6:32 PM |
| Ocera Therapeutics, Inc. (OCRX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 16 at 8:48 AM |
| Ocera Therapeutics Inc (OCRX) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - June 7 at 4:42 PM |
 | Ocera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis - StreetInsider.com
www.streetinsider.com - June 2 at 9:02 PM |
| Ocera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis
www.streetinsider.com - June 1 at 7:48 PM |
| Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
finance.yahoo.com - June 1 at 7:48 PM |
 | Ocera Therapeutics to Host KOL Conference Call on Hepatic ... - Nasdaq
www.nasdaq.com - May 26 at 7:58 PM |
| Ocera Therapeutics Inc (OCRX) Rating Reiterated by Aegis
www.americanbankingnews.com - May 24 at 9:38 AM |
| Ocera Therapeutics Inc (OCRX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 22 at 8:18 AM |
| Ocera Therapeutics Inc (OCRX) Short Interest Update
www.americanbankingnews.com - May 18 at 9:24 PM |
| Ocera Therapeutics Inc (OCRX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 18 at 9:02 PM |
| Ocera Therapeutics Inc (OCRX) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - May 14 at 4:34 PM |
| Ocera Therapeutics' (OCRX) CEO Linda Grais on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 13 at 8:17 AM |
| Ocera Therapeutics (OCRX) Reports Q1 Loss Per Share of $0.28, Offers Guidance
www.streetinsider.com - May 12 at 12:30 AM |
| Edited Transcript of OCRX earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 7:28 PM |
| Zacks: Analysts Anticipate Ocera Therapeutics Inc (OCRX) Will Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - May 11 at 6:28 PM |
| Ocera Therapeutics Inc (OCRX) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 10 at 6:40 PM |
| Investor Network: Ocera Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 6:35 PM |
| Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update
finance.yahoo.com - May 9 at 6:35 PM |
| Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017
finance.yahoo.com - May 3 at 8:03 PM |
| ETFs with exposure to Ocera Therapeutics, Inc. : May 3, 2017
finance.yahoo.com - May 3 at 8:03 PM |
| Ocera Therapeutics (OCRX) Getting Somewhat Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - May 3 at 2:14 PM |
| Somewhat Favorable Media Coverage Likely to Impact Ocera Therapeutics (OCRX) Share Price
www.americanbankingnews.com - April 30 at 4:10 PM |
| Ocera Therapeutics (OCRX) Receiving Somewhat Critical Media Coverage, Study Shows
www.americanbankingnews.com - April 24 at 6:26 PM |
| Brokerages Expect Ocera Therapeutics Inc (OCRX) Will Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - April 20 at 10:18 PM |
| ETFs with exposure to Ocera Therapeutics, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 7:00 PM |
| Ocera Therapeutics (OCRX) Given Media Sentiment Score of 0.28
www.americanbankingnews.com - April 19 at 12:59 PM |
| Ocera Therapeutics' (OCRX) "Buy" Rating Reaffirmed at Aegis
www.americanbankingnews.com - April 17 at 10:32 AM |
| Ocera Therapeutics (OCRX) Getting Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 16 at 2:35 PM |
| Short Interest in Ocera Therapeutics Inc (OCRX) Declines By 32.1%
www.americanbankingnews.com - April 16 at 7:08 AM |
| BUZZ-U.S. STOCKS ON THE MOVE-Wells Fargo, HanesBrands ... - Nasdaq
www.nasdaq.com - April 13 at 11:47 PM |
| Somewhat Positive Press Coverage Likely to Effect Ocera Therapeutics (OCRX) Stock Price
www.americanbankingnews.com - April 13 at 6:15 PM |
| After-Hours Stock Movers 04/12: (OCRX) (AAOI) (HBI) Higher; (SRNE) (DMPI) (PIR) Lower (more...) - StreetInsider.com
www.streetinsider.com - April 13 at 8:04 AM |
| Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in …
finance.yahoo.com - April 12 at 7:55 PM |
| Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)
finance.yahoo.com - April 12 at 7:55 PM |
| ETFs with exposure to Ocera Therapeutics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 7:24 PM |
| OCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
biz.yahoo.com - March 31 at 7:05 PM |
| Ocera to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 27 at 6:29 PM |
| Ocera Therapeutics Inc (OCRX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:03 PM |
| OCERA THERAPEUTICS, INC. Financials
finance.yahoo.com - March 18 at 6:25 PM |
| OCERA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 14 at 6:30 PM |
| Ocera Therapeutics, Inc.: Yet Another Step Towards Putting a New Drug Treatment for Chronic Orphan Liver Diseases
finance.yahoo.com - March 13 at 9:59 AM |
| Mid-Aternoon Market Update: Crude Oil Down 1.5%; Citi Trends Shares Rise On Earnings Beat
www.nasdaq.com - March 10 at 8:45 PM |
Ocera Therapeutics (OCRX) Chart for Saturday, August, 19, 2017
